ArticleCancer science2023

Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.

Toshihiko Doi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.